Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $350000.0.

  • Precision Biosciences' Depreciation & Amortization (CF) fell 5104.9% to $350000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 6270.99%. This contributed to the annual value of $3.4 million for FY2024, which is 5006.6% down from last year.
  • As of Q3 2025, Precision Biosciences' Depreciation & Amortization (CF) stood at $350000.0, which was down 5104.9% from $378000.0 recorded in Q2 2025.
  • Precision Biosciences' 5-year Depreciation & Amortization (CF) high stood at $2.4 million for Q2 2021, and its period low was $350000.0 during Q3 2025.
  • In the last 5 years, Precision Biosciences' Depreciation & Amortization (CF) had a median value of $1.9 million in 2022 and averaged $1.5 million.
  • As far as peak fluctuations go, Precision Biosciences' Depreciation & Amortization (CF) skyrocketed by 739.9% in 2021, and later tumbled by 6544.18% in 2025.
  • Over the past 5 years, Precision Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $2.2 million in 2021, then dropped by 9.89% to $2.0 million in 2022, then crashed by 34.74% to $1.3 million in 2023, then crashed by 64.5% to $454000.0 in 2024, then dropped by 22.91% to $350000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $350000.0 in Q3 2025, compared to $378000.0 in Q2 2025 and $395000.0 in Q1 2025.